On Friday, Shares of Halliburton Company (NYSE:HAL), lost -0.87% to $43.12, as oil prices decline ahead of Iranian nuclear talks.
WTI crude oil for August delivery was down 1.2% to $58.96 a barrel Friday morning, and Brent crude oil for August delivery was down 0.9% to $62.65 a barrel.
Oil prices were falling Friday as investors wait for the outcome of Iranian nuclear talks, according to Reuters. A nuclear deal with the country could lead to an enhance in crude exports from the country while the market is already over-supplied with crude oil.
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation.
Shares of The Charles Schwab Corporation (NYSE:SCHW), inclined 0.84% to $33.53, during its last trading session.
Speaking from the main stage to a group of nearly 180 independent registered investment advisors (RIAs) at its annual EXPLORE™ conference on June 25, Bernie Clark, executive vice president and head of Schwab Advisor Services, commended them on their continued growth, noting that “the industry is in a position of undeniable strength.” He also struck a tone of urgency, telling advisors complacency has no place in the RIA industry given the exponential enhance in the speed of change and the knowledge that the ways in which advisors compete and serve clients today will be different tomorrow.
During the course of his remarks, Clark commented on the industry’s success and the fact that RIAs have won the trust of clients — evidenced by the average 97 percent retention rate1 of clients year-over-year that advisors report and by the fact that client referrals continue to drive organic growth.
The Charles Schwab Corporation, through its auxiliaries, provides wealth administration, securities brokerage, banking, money administration, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services.
Finally, Celladon Corporation (NASDAQ:CLDN), ended its last trade with -38.64% loss, and closed at $1.35, hitting its lowest level.
Celladon Corporation, confirmed its plans to suspend further research or development of its MYDICAR (AAV1/SERCA2a) program and its other pre-clinical programs counting the Stem Cell Factor (mSCF) gene therapy and SERCA2b small molecule programs.
Earlier in the month the Company declared the engagement of Wedbush PacGrow Healthcare as its exclusive financial advisor and a planned plan following which the Company right away commenced a process to seek a merger or sale. This process is ongoing and the Company anticipates to provide further updates on the progress of this planned plan in the coming quarter, which could comprise the sale of the Company or some or all of its assets, and/or a liquidation and distribution of the remaining cash to its shareholders.
The Company presently estimates that if it were to liquidate during the third quarter of 2015, the net cash accessible for distribution to shareholders would be about $25-$30 million. This projection is based on the Company’s current expectations and assumptions, and the actual amount of net cash accessible for distribution in such a liquidation and distribution could differ materially from the Company’s current estimate.
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, in addition to to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
